To develop a protein-protein interaction network of rectal cancer, which is based on genetic genes as well as to predict biological pathways underlying the molecular complexes in the network. In order to analyze and summarize genetic markers related to diagnosis and prognosis of rectal cancer.
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Network topology attribute analysis
Network topology attribute analysis shown that the connectivity of nodes in the network (the number of nodes in the network ) obeys descending distribution, i.e. with the increase of edges connected to the node, correspondingly the number of nodes decrease , so it can be seen that the gene -protein interaction networks are scale-free networks [15] . We found that the connectivity of nodes in the network greater than or equal to 25 corresponds to a sharp reduction in the number of nodes Rank1 score20 Node20 Edges190
Rank2 score20 Node20 Edges190
Rank3 score14 Node14 Edges91
Rank4 score11.662 Node78 Edges449
Rank5 score3.143 Node21 Edges66
Rank6 score9 Node9 Edges36
Rank7 score7.673 Node56 Edges221
Figure 5 Molecular complexes obtained by MCOMD algorithm analysis
The details of the relationship of proteins in molecular complexes 7 was shown in Figure 6 Figure6 the relationship of proteins in molecular complexes 7
The whole network has a total of six parts, including mitogen-activated protein kinase, Specific microRNAs, SRY-related HMG-box, matrix metalloproteinases, cyclinD.
2.5Molecular complex pathway enrichment
Submit the 7 names of protein molecule complexes online to obtain the relevant pathways in Table 2 .The Protein molecule biological pathways of complexes 1 are not exist,and other complexes contain different pathways.Regulatory effects of genes and proteins mainly focused on cell cycle, transcription regulation, and cellular protein metabolic process.
cluster1(score 20) in the centre, have closely relationships with each other as well as other genes.
It has reported that the secreted protein acidic and rich in cysteine-like 1 (,sparcl1) is expressed in various normal tissues and many types of cancers. Another study has shown that marker sparcl1
was significantly related to the prognosis and clinical pathological features of the CRC patients [27] . Sparcl1 expression increased with RT and is related to a better prognosis in rectal cancer patients with RT but not in patients without RT. This result may help us to select the patients to the best suited preoperative RT. In the process of rectal cancer, gene WISP2 knockout significantly increased Caco-2 cell invasion and motility. Up-regulation of MMP2, -7 and -9 may indicate that WISP2regulates invasion and motility through MMPs. Regulation of invasion by WISP2 may involve the WNT signalling pathway [28] . Thus, some studies have identified CUX1 as a pan-driver of tumorigenesis and uncover a potential strategy for treating CUX1-mutant tumors. So from cluster1 we predict the effect of gene Cut1 to rectal cancer may be that CUX1 deficiency activates phosphoinositide 3-kinase (PI3K) signalling through direct transcriptional downregulation of the PI3K inhibitor PIK3IP1 (phosphoinositide-3-kinase interacting protein 1), leading to increased tumor growth and susceptibility to PI3K-AKT inhibition. And we also can forecast a few clones existing in colorectal cancer, containing gene mutation of ptk2, htra1 and PABPC1.
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